Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Louisiana Health Service & Indemnity Company et al v. Janssen Biotech, Inc. et al
Case Number:
1:19-cv-00474
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
June 21, 2019
Va. Suits Alleging Janssen Cancer Drug 'Monopoly' Sent To NJ
A Virginia federal judge on Friday combined several class actions accusing Janssen Biotech of monopolizing sales of cancer drug Zytiga and sent them to New Jersey, saying not only does the case belong there but she doesn't want to overcrowd the Old Dominion court's docket.
-
June 07, 2019
Janssen OK With Combining Zytiga Suits If They're Sent To NJ
Janssen Biotech told a Virginia federal court that it's fine if several proposed classes want to combine their suits accusing the pharmaceutical company of delaying the entry of a generic version of its prostate cancer drug Zytiga, as long as the case gets moved to New Jersey.
-
June 03, 2019
Proposed Classes Ask To Combine Janssen Antitrust Suits
Four proposed classes suing Janssen Biotech for allegedly using sham patent litigation to keep a generic version of its prostate cancer drug off the market want a Virginia federal court to consolidate their suits so they can team up against the pharmaceutical giant.
-
May 28, 2019
Blue Cross' Antitrust Suit Belongs In NJ, Janssen Says
Blue Cross Blue Shield should have to pursue its claims that Janssen Biotech used "sham" patent infringement litigation to delay generic competition to prostate cancer drug Zytiga in front of the same federal judge who oversaw the patent lawsuit, the drugmaker has argued.
-
April 19, 2019
Blue Cross Attacks Janssen Prostate Cancer Drug 'Monopoly'
Blue Cross Blue Shield accused Janssen Biotech of misusing patent infringement suits to keep generic versions of prostate cancer drug Zytiga at bay, telling a Virginia federal judge the drug giant tricked the government into issuing a new patent on the treatment.